FdaApplication
NDA 202379
Identifiers
- fda_app_no: NDA202379
Properties
| Property | Value |
|---|---|
| applicant_name | JANSSEN BIOTECH INC |
| application_type | NDA |
| approval_date | 2011-04-28 |
Revenue by product
ZYTIGA
| Period | Revenue |
|---|---|
| Q4 2025 | $119.0M |
| Q3 2025 | $113.0M |
| Q2 2025 | $145.0M |
| Q1 2025 | $125.0M |
| Q4 2024 | $135.0M |
| Q3 2024 | $150.0M |
| Q2 2024 | $165.0M |
| Q1 2024 | $181.0M |
| Q4 2023 | $201.0M |
| Q3 2023 | $214.0M |
| Q2 2023 | $227.0M |
| Q1 2023 | $245.0M |
| Q4 2022 | $270.0M |
| Q3 2022 | $456.0M |
| Q2 2022 | $505.0M |
| Q1 2022 | $539.0M |
| Q4 2021 | $548.0M |
| Q3 2021 | $548.0M |
| Q2 2021 | $563.0M |
| Q1 2021 | $638.0M |
| Q4 2020 | $622.0M |
| Q3 2020 | $590.0M |
| Q2 2020 | $568.0M |
| Q1 2020 | $690.0M |
| Q4 2019 | $677.0M |
| Q3 2019 | $741.0M |
| Q2 2019 | $698.0M |
| Q1 2019 | $679.0M |
| Q4 2018 | $786.0M |
| Q3 2018 | $958.0M |
| Q2 2018 | $909.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ZYTIGA | ABIRATERONE ACETATE | 500MG | TABLET;ORAL |
| ZYTIGA | ABIRATERONE ACETATE | 250MG | TABLET;ORAL |
2 products